© 2022 MJH Life Sciences and NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Klaus Schmierer, MB BS, PhD, FRCP, discusses how patients with multiple sclerosis have been impacted by the COVID-19 pandemic, including guideline recommendations regarding vaccinations.
March 11th 2022
Klaus Schmierer, MB BS, PhD, FRCP, defines the pathophysiology of multiple sclerosis (MS).
Dr Schmierer introduces the disease-modifying therapies (DMT) that are available for patients with MS and their impact on the immune system.
March 18th 2022
Dr Schmierer explains how the SARS-CoV-2 infection and COVID-19 pandemic have impacted treating patients with MS with DMTs.
An expert delves into the different types of immune responses a patient with MS can have to COVID-19 vaccines if they are also on DMTs.
March 28th 2022
Dr Schmierer discusses the general guideline vaccination recommendations for patients with MS.
Klaus Schmierer, MB BS, PhD, FRCP, concludes with advice for community physicians and neurologists who are managing patients with MS and COVID-19 or vaccinations.
The Success of the Jefferson Mobile Stroke Unit: Alvin Wang, DO, BC-EMS
Progress in Neurogenerative Disease Drug Development: Gregory A. Rippon, MD, MS
Diazepam Nasal Spray Significantly Extends Time Between Seizure Clusters
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc